We are also assessing whether or not labeling modifications are required for other CNS depressants, and can update the general public when additional information is available. Depending on the trends of enhanced concomitant use of opioid analgesics and benzodiazepines and also improved harms affiliated with concomitant use explained in https://benzodiazepines-llist-of52739.techionblog.com/34713493/benzodiazepines-for-anxiety-treatment